Large Real-World Evidence Analysis Demonstrates that Zio® XT Is Associated With the Highest Diagnostic Yield, Lowest Retesting Rates, and Fastest Time to Clinical Diagnosis Compared to Other Ambulatory ECG Monitors

About this update from Irhythm Holdings, Inc.

[{"type":"text","content":"Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio suite of products and services\nSAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, recently presented the results of multiple new studies at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC). The CAMELOT study, titled “Comparative Effectiveness Of Ambulatory Monitors For Arrhythmia Diagnosis: A Retrospective Analysis Of Medicare Beneficiaries,” demonstrated that: Long-term continuous monitoring (LTCM) with Zio XT is associated with the highest diagnostic yield and the fastest time to clinical diagnosis compared to all other ambulatory cardiac monitors (ACM) when looking at specified arrhythmias.Zio XT has the lowest likelihood of retesting compared to all other ACMs.Zio XT is associated with the lowest acute care healthcare resource utilization compared to all other ACMs. The CAMELOT study is the largest and most contemporary real-world, comparative effectiveness analysis1,2 of ambulatory cardiac monitoring. Using a full (100%) sample of Medicare data, the study sought to evaluate yield of clinical diagnosis, retesting rates, and health care utilization across four categories of ambulatory cardiac monitoring: Holter, long-term continuous monitoring (LTCM), mobile cardiac telemetry (MCT), and ambulatory event monitor. The principal finding is that Zio XT, prescribed for up to 14 days of monitoring, is associated with the highest diagnostic yield and fastest time to diagnosis, lowest odds of 180-day retesting, and the lowest risk of emergency department and inpatient hospitalization compared to Holter, MCT, ambulatory event monitors, and other LTCM services. “Ambulatory external ECG monitoring is being widely used in clinical practice. Providers have choices of various types of ECG monitors, as well as choice of several vendors. There has previously been no attempt to determine whether these choices influence important endpoints such as diagnostic yield or need for re-testing,” said Suneet Mittal, MD, director of electrophysiology at Valley Health System and presenting author of the study. “The CAMELOT study provides real wor...

More updates from Irhythm Holdings, Inc.